Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-021640
Filing Date
2022-11-03
Accepted
2022-11-03 10:53:51
Documents
104
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q atnx-20220930.htm   iXBRL 10-Q 5426131
2 EX-4.1 atnx-ex4_1.htm EX-4.1 217960
3 EX-4.2 atnx-ex4_2.htm EX-4.2 225193
4 EX-10.5 atnx-ex10_5.htm EX-10.5 34280
5 EX-31.1 atnx-ex31_1.htm EX-31.1 25661
6 EX-31.2 atnx-ex31_2.htm EX-31.2 25040
7 EX-32.1 atnx-ex32_1.htm EX-32.1 17820
  Complete submission text file 0000950170-22-021640.txt   21729369

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT atnx-20220930_cal.xml EX-101.CAL 100460
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT atnx-20220930_def.xml EX-101.DEF 479147
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT atnx-20220930_lab.xml EX-101.LAB 896268
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT atnx-20220930_pre.xml EX-101.PRE 699982
12 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT atnx-20220930.xsd EX-101.SCH 120371
98 EXTRACTED XBRL INSTANCE DOCUMENT atnx-20220930_htm.xml XML 5045422
Mailing Address 1001 MAIN STREET SUITE 600 BUFFALO NY 14203
Business Address 1001 MAIN STREET SUITE 600 BUFFALO NY 14203 716-898-8625
Athenex, Inc. (Filer) CIK: 0001300699 (see all company filings)

EIN.: 431985966 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38112 | Film No.: 221356787
SIC: 2834 Pharmaceutical Preparations